StreetInsider.com News Articles

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Garzone Pamela

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998957.html

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Garzone Pamela

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998957.html

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Sarraf Pasha

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998964.html

Form 4/A Cue Biopharma, Inc. For: Jul 09 Filed by: Sarraf Pasha

Fri, 28 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260828/26998964.html

Cue Biopharma (CUE) PT Raised to $66 at Jefferies

Fri, 28 Aug 2026 07:58:44 -0400

Jefferies analyst Maury Raycroft raised the price target on Cue Biopharma (NASDAQ: CUE) to $66.00 (from $4.00) while maintaining a Buy rating.

Form SCHEDULE 13D Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Fri, 21 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260821/26962167.html

Form SCHEDULE 13D Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Fri, 21 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260821/26962167.html

Form EFFECT Cue Biopharma, Inc.

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958176.html

Form EFFECT Cue Biopharma, Inc.

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958176.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Ray Sumita

Mon, 17 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26939171.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Ray Sumita

Mon, 17 Aug 2026 18:23:00 -0400

si-local-file:///var/storage/secattach/20260817/26939171.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Meluzio Michael Vincent

Mon, 17 Aug 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260817/26939163.html

Form 4 Cue Biopharma, Inc. For: Aug 13 Filed by: Meluzio Michael Vincent

Mon, 17 Aug 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260817/26939163.html

Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c

Mon, 17 Aug 2026 06:26:51 -0400

Cue Biopharma, Inc. (NASDAQ: CUE) reported Q2 EPS of ($24.14), $20.54 worse than the analyst estimate of ($3.60). Revenue for the quarter came in at $7.88 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Cue Biopharma, Inc. (CUE) click here.

Form 4 Cue Biopharma, Inc. For: Aug 12 Filed by: Lin Shao-Lee

Fri, 14 Aug 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26933284.html

Form 4 Cue Biopharma, Inc. For: Aug 12 Filed by: Lin Shao-Lee

Fri, 14 Aug 2026 20:46:00 -0400

si-local-file:///var/storage/secattach/20260814/26933284.html

Form 144 Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Fri, 14 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26933283.html

Form 144 Cue Biopharma, Inc. Filed by: Lin Shao-Lee

Fri, 14 Aug 2026 20:45:00 -0400

si-local-file:///var/storage/secattach/20260814/26933283.html

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Fri, 14 Aug 2026 16:05:00 -0400

Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications
Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflection
Strengthened the leadership team with the appointments of the Chief Medical Officer and Head of R&D and the Chief Financial Officer
Operating results reflected higher expenditures related to the licensing and initiation of the CUE-221 development program, driven by one-time non-cash charges and acquisition-related payments